Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 8

recruiting
3 987
countries
28
conditions
2 109

123 trials match your criteria

Malignant melanoma

Not recruiting

Study Comparing Naporafenib and Trametinib Combination to Other Therapies for Patients with Previously Treated Unresectable or Metastatic NRAS Mutant Melanoma

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Dacarbazine

Transitional cell carcinoma

Not recruiting

Study of BT8009 Alone or with Pembrolizumab for Patients with Advanced or Metastatic Bladder Cancer

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab

Malignant melanoma stage IV+1

Not recruiting

Study of Nivolumab and Relatlimab for Patients with Stage III-IV Melanoma After Surgery

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nivolumab

Non-small cell lung cancer+2

Not recruiting

Study of Niraparib and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab

Colitis ulcerative

Not recruiting

Study on the Effectiveness and Safety of Guselkumab for Children with Moderate to Severe Ulcerative Colitis

Investigational
Countries:NorwayNorway
  • Participants:0–17 years
  • Substances:Guselkumab

Transitional cell carcinoma

Not recruiting

Study on Nivolumab and Ipilimumab for Patients with Untreated Unresectable or Metastatic Urothelial Cancer

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Migraine+1

Not recruiting

Study of Eptinezumab as Add-on Treatment for Prevention of Migraine in Adults with Both Migraine and Medication Overuse Headache

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Eptinezumab

Colorectal cancer metastatic

Not recruiting

Study Comparing Nivolumab, Nivolumab with Ipilimumab, or Chemotherapy for Patients with Metastatic Colorectal Cancer with High Microsatellite Instability

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab

Cardiac amyloidosis

Not recruiting

Study on the Effectiveness and Safety of ALXN2220 for Adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Investigational
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:ALXN2220

Plasma cell myeloma

Not recruiting

Study on Alnuctamab and Drug Combination for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Alnuctamab

Idiopathic pulmonary fibrosis

Not recruiting

Long-Term Study of BI 1015550 for Patients with Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:BI 1015550

Chronic obstructive pulmonary disease

Not recruiting

Study on Long-Term Safety of Itepekimab for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Investigational
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Itepekimab

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.